News | News By Subject | News by Disease News By Date | Search News

Renal Cell Carcinoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Cerulean (CERU) Shares Decimated as Renal Cell Carcinoma Drug Comes Up Short in Mid-Stage Study     8/18/2016
Pfizer (PFE) Stock Climbs With Positive Renal Cancer Phase III Data     7/8/2016
Mologen (MOLGF.PK) Restructures, Pushes Immunology Program, Shelves Renal Cancer Vaccine     6/9/2016
Exelixis (EXEL)' Cabozantinib Met Primary Endpoint in Phase II Renal Cell Carcinoma Study     5/23/2016
Exelixis (EXEL)'s Cabozantinib Shines in Late Stage Study for Patients with Advanced RCC     1/6/2016
AVEO Oncology (AVEO), EUSA Pharma Form $396.5 Million Exclusive Licensing Agreement for Tivozanib in Europe     12/21/2015
Bristol-Myers Squibb (BMY) Grabs Breakthrough Tag for Opdivo     9/16/2015
Revitalized Exelixis (EXEL) Grabs Breakthrough Tag for Cabozantinib     8/25/2015
Bristol-Myers Squibb (BMY)'s Opdivo Phase III Study Stopped Early on More Good Cancer Therapy News     7/21/2015
Embattled Exelixis (EXEL) Nabs Much-Needed Victory for Phase III Renal Cell Carcinoma Study     7/21/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test     3/19/2014
FDA Committee Turns Down AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO)/Astellas Pharma Inc. (YPH.BE)'s Cancer Drug     5/6/2013
Pfizer Inc. (PFE) Kidney Cancer Drug Fails as Initial Treatment     10/18/2012

News from Around the Web

Press Releases
Cerulean (CERU) Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin Combination In Relapsed Renal Cell Carcinoma     8/18/2016
AVEO Oncology (AVEO) Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) In Advanced Renal Cell Carcinoma     8/15/2016
Omeros (OMER) Confirms OMS721 Phase 3 Development Plan With EMA     7/28/2016
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Receive Positive CHMP Opinion For Cabometyx (Cabozantinib) For The Treatment Of Advanced RCC In Adults Following Prior VEGF-Targeted Therapy     7/22/2016
Celldex (CLDX) Initiates Phase I/II Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma     7/12/2016
Cerulean Pharma Inc. (CERU) Announces Manuscript Published in Annals of Oncology     6/9/2016
ASCO2016: Exelixis (EXEL) And Its Partner Ipsen (IPN.PA) Announce Positive Overall Survival Results From Subgroup Analyses Of Phase III Trial Of CABOMETYX (Cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting     6/6/2016
Novartis Pharmaceuticals Corporation (NVS) Announces US Collaboration To Co-Promote Lenvima In Combination With Everolimus For Advanced Renal Cell Carcinoma (RCC)     6/3/2016
Eisai Inc. (ESALF.PK) Enters Into A Collaboration Agreement To Co-Promote LENVIMA (Lenvatinib) In Combination With Everolimus In The U.S.     6/3/2016
Ipsen (IPN.PA)’s Partner Exelixis (EXEL) Announced Results From Randomized Phase 2 Trial CABOSUN That Demonstrate That Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma     5/24/2016
Rexahn Pharmaceuticals, Inc. (RNN) To Present At The ASCO 2016 Annual Meeting     5/23/2016
FDA Approves Eisai Inc. (ESALF.PK)'s LENVIMA (Lenvatinib) For The Treatment Of Patients With Advanced Renal Cell Carcinoma In Combination With Everolimus Following Prior Anti-Angiogenic Therapy     5/16/2016
Mirna Reports First Quarter 2016 Financial Results And Program Updates     5/13/2016
AVEO Oncology (AVEO) Reports First Quarter 2016 Financial Results And Provides Business Update     5/11/2016
X4 Pharma Announces Initiation Of Phase 1/2 Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma     5/9/2016

//-->